Holen Sie sich die Stockscreener-App
15.64
5.83%
-1.00
Handel nachbörslich:
15.62
-0.02
-0.13%
Schlusskurs vom Vortag:
$16.64
Offen:
$16.31
24-Stunden-Volumen:
1.23M
Relative Volume:
1.46
Marktkapitalisierung:
$1.66B
Einnahmen:
$247.00M
Nettoeinkommen (Verlust:
$-249.00M
KGV:
-5.0615
EPS:
-3.09
Netto-Cashflow:
$-267.00M
1W Leistung:
+11.69%
1M Leistung:
+36.02%
6M Leistung:
+104.04%
1J Leistung:
-13.38%
1-Tages-Spanne:
$15.42
$16.45
1-Wochen-Bereich:
$14.18
$17.19
52-Wochen-Spanne:
$6.50
$18.98
Arcus Biosciences Inc Stock (RCUS) Company Profile
Firmenname
Arcus Biosciences Inc
Sektor
Branche
Telefon
(510) 694-6200
Adresse
3928 POINT EDEN WAY, HAYWARD, CA
Vergleichen Sie RCUS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RCUS
Arcus Biosciences Inc
|
15.62 | 1.55B | 247.00M | -249.00M | -267.00M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Arcus Biosciences Inc Stock (RCUS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-26 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2024-10-21 | Eingeleitet | H.C. Wainwright | Neutral |
| 2024-10-08 | Eingeleitet | Wells Fargo | Overweight |
| 2022-11-18 | Eingeleitet | BofA Securities | Neutral |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2020-11-24 | Eingeleitet | Berenberg | Buy |
| 2020-11-23 | Eingeleitet | Evercore ISI | Outperform |
| 2020-04-03 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-09-27 | Eingeleitet | Mizuho | Buy |
| 2019-05-24 | Fortgesetzt | Citigroup | Buy |
| 2018-10-09 | Eingeleitet | Wedbush | Outperform |
| 2018-04-09 | Eingeleitet | Citigroup | Buy |
| 2018-04-09 | Eingeleitet | Goldman | Neutral |
| 2018-04-09 | Eingeleitet | Leerink Partners | Outperform |
Alle ansehen
Arcus Biosciences Inc Aktie (RCUS) Neueste Nachrichten
Arcus’s ‘Last TIGIT Standing’ Shows Phase II Survival Benefit - insights.citeline.com
Arcus Biosciences Reports Promising Phase 2 Study Results - TipRanks
Arcus Biosciences reports Phase 2 survival data for gastric cancer study By Investing.com - Investing.com South Africa
Arcus Biosciences reports Phase 2 survival data for gastric cancer study - Investing.com
Arcus Biosciences Announces Phase 2 Study Results - TradingView
Will Arcus Biosciences Inc. outperform the marketQuarterly Trade Review & Technical Pattern Based Buy Signals - newser.com
Visual analytics tools that track Arcus Biosciences Inc. performanceQuarterly Earnings Report & Weekly Consistent Profit Watchlists - newser.com
Gilead and Arcus see survival boost with gastric cancer combo - The Pharma Letter
Why Arcus Biosciences Inc. stock is rated strong buyEarnings Overview Report & Advanced Swing Trade Entry Plans - newser.com
Arcus Biosciences (RCUS) Is Up 14.9% After Positive Phase 2 Survival Data in Gastric Cancer—What's Changed - Yahoo Finance
Citigroup Raises Price Target for RCUS to $54, Maintains Buy Rat - GuruFocus
Arcus Biosciences stock rises after strong gastric cancer survival data - Investing.com
Arcus Biosciences (RCUS) Shares Surge Following Positive Study R - GuruFocus
Arcus Biosciences rises on results from domvanalimab cancer study - Seeking Alpha
Gilead Sciences/Arcus Biosciences' Investigational Cancer Drug Shows Overall Survival Of Around 27 Months - Benzinga
What MACD signals say about Arcus Biosciences Inc.2025 Key Lessons & Weekly High Potential Stock Alerts - newser.com
Sector Update: Health Care Stocks Higher Premarket Monday - MarketScreener
Applying sector rotation models to Arcus Biosciences Inc.July 2025 Sentiment & Expert Verified Movement Alerts - newser.com
Arcus Biosciences (RCUS) Reveals Promising Phase 2 Gastric Cance - GuruFocus
Arcus Biosciences Turns Heads With 26.7-Month Survival In Gastric Cancer Study — Retail Calls It ‘Unprecedented’ - Stocktwits
Arcus Biosciences to present promising gastric cancer survival data - Investing.com
Arcus Bioscience announces first overall survival results from phase 2 edge-gastric study - MarketScreener
Arcus Biosciences Shows 26.7‑Month Median OS in EDGE‑Gastric | RCUS Stock News - Stock Titan
Will Arcus Biosciences Inc. stock benefit from sector rotationJuly 2025 Highlights & Weekly Breakout Opportunity Watchlist - newser.com
Price momentum metrics for Arcus Biosciences Inc. explainedWeekly Trend Summary & AI Driven Price Predictions - newser.com
Arcus Biosciences (NYSE:RCUS) COO Jennifer Jarrett Sells 37,792 Shares of Stock - MarketBeat
Arcus Biosciences Announces New Employment Inducement Grants - MarketScreener
60,300 Options at $15.05 — Arcus Biosciences Grants 30,150 RSUs under 2020 Inducement Plan - Stock Titan
Arcus Biosciences Hits Day High with Strong 7.27% Intraday Surge - Markets Mojo
Arcus Biosciences Hits Day High with Strong 8.46% Intraday Surge - Markets Mojo
Arcus Biosciences’ SWOT analysis: oncology firm’s stock faces pivotal data By Investing.com - Investing.com Australia
Arcus Biosciences COO Jarrett sells $750k in shares By Investing.com - Investing.com Canada
Arcus Biosciences’ SWOT analysis: oncology firm’s stock faces pivotal data - Investing.com India
Arcus Biosciences (RCUS) Soars 8.5%: Is Further Upside Left in the Stock? - MSN
Weiss Ratings Reaffirms "Sell (D-)" Rating for Arcus Biosciences (NYSE:RCUS) - MarketBeat
Cantor Fitzgerald reiterates Overweight rating on Arcus Biosciences stock By Investing.com - Investing.com Canada
RCUS: Truist Securities Raises Price Target for Arcus Biosciences | RCUS Stock News - GuruFocus
How Arcus Biosciences Aims To Take On Merck In Cancer Treatment - inkl
A Fresh Look at Arcus Biosciences (RCUS) Valuation After New Casdatifan Data and Expanded Pipeline Initiatives - Yahoo Finance
Arcus Biosciences announces new anti-inflammation programs - BioWorld MedTech
Truist Raises Price Target on Arcus Biosciences to $39 From $32, Keeps Buy Rating - MarketScreener
Arcus Biosciences Presents Promising ARC-20 Study Data - MSN
Why Is Arcus Biosciences Stock Trading Higher On Monday? - Sahm
Arcus Biosciences (NYSE:RCUS) Trading Up 15.2%Here's What Happened - MarketBeat
Transcript : Arcus Biosciences, Inc.Shareholder/Analyst Call - MarketScreener
Arcus Biosciences (RCUS) Sees Promising Results in Latest Study - GuruFocus
Arcus Biosciences (RCUS) Shares Positive Data on Casdatifan for Metastatic RCC - GuruFocus
Arcus Biosciences presents new data for its HIF-2a inhibitor casdatifan - MarketScreener
Arcus Biosciences reports positive casdatifan data, expands into inflammation - StreetInsider
Can momentum traders help lift Arcus Biosciences Inc.Weekly Stock Recap & Weekly High Return Forecasts - newser.com
What drives Arcus Biosciences Inc stock priceSector Performance Drivers & Free Superior Stock Performance - earlytimes.in
Finanzdaten der Arcus Biosciences Inc-Aktie (RCUS)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.47%
1.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):